1130P Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Léah Mailly-Giacchetti(Inserm), Manuel Rodrigues(Inserm), J-C. Thery(Centre Virchow-Villermé), Marc Pracht(Canadian Partnership Against Cancer), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), N. Litrowski, Sylvaine Renault(Institut Curie), Mathilde Saint‐Ghislain(Centre Oscar Lambret), Leanne de Koning(Université Paris Sciences et Lettres), Hélène Martin(Centre National de la Recherche Scientifique), T. Ramtohul(Institut Curie), Sophie Piperno‐Neumann(Institut Curie), P-F. Combe(Pôle Léonard de Vinci), Vincent Servois(Université Paris Sciences et Lettres)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k